INMB Q1 2018 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$37M

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$3M

Net Income

-$3M

EPS (Diluted)

$-0.25

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$328,841

Free Cash Flow

-$328,841

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$19M

Total Liabilities

$196,366

Stockholders' Equity

$19M

Cash & Equivalents

$2M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$3M	-$119,450	-2282.6%
Net Income	-$3M	$30,550	-9415.9%